Showing 1201-1210 of 1583 results for "".
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchange, Raises $50Mhttps://modernaesthetics.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange-raises-50m/2473109/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Forget Injectables, Patients with Benign Skin Lesions Want Them Gonehttps://modernaesthetics.com/news/forget-injectables-patients-with-benign-skin-lesions-prioritize/2473097/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- PCA Skin Gears Up for National Peel Dayhttps://modernaesthetics.com/news/pca-skin-gears-up-for-national-peel-day/2473068/Next week brings the second annual National Peel Day. To coincide with the official holiday recognized by the National Day Archives on the National Day Registry on March 10, PCA Skin will unveil new branding this month. Among various social media ac
- Industry Responds to COVID-19: Biopelle, Galderma US Aestheticshttps://modernaesthetics.com/news/industry-responds-to-covid-19-biopelle-galderma-us-aesthetics/2473063/Biopelle One bright spot for many aesthetic practices during the COVID-19 pandemic has been persistent and perhaps increased demand for skincare. Biopelle has responded to support physicians who wish to dispense their products. “We offer a ski
- FDA Greenlights Galderma's Restylane Defyne for Chin Augmentationhttps://modernaesthetics.com/news/fda-greenlights-galdermas-restylane-defyne-for-chin-augmentation/2473055/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Ransomware Alert: Government Advisory Suggests Threat to Healthcare Systemhttps://modernaesthetics.com/news/ransomware-alert-government-advisory-suggests-threat-to-healthcare-system/2473012/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- AmSpa Releases New Guidelines, To Host Educational Programhttps://modernaesthetics.com/news/amspa-releases-new-guidelines-to-host-educational-program/2472994/
- Amore Pacific Gets Woke with Enough Project Lifestyle Brandhttps://modernaesthetics.com/news/amore-pacific-gets-woke-with-enough-project-lifestyle-brand/2472983/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In a
- New from Cutera: Get to Know Fraxis PROhttps://modernaesthetics.com/news/new-from-cutera-get-to-know-fraxis-pro/2472965/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines Wr